» Articles » PMID: 38355422

Prevalence and Drug Use Correlates of Inadvertent Fentanyl Exposure Among Individuals Misusing Drugs in Seven U.S. States

Overview
Journal J Addict Dis
Publisher Informa Healthcare
Date 2024 Feb 14
PMID 38355422
Authors
Affiliations
Soon will be listed here.
Abstract

Fentanyl has emerged as the leading cause of fatal drug overdoses in the U.S. Individuals misusing drugs may not always be aware of exposure to fentanyl. To determine the prevalence of fentanyl use and extent of awareness of fentanyl exposure among a national sample of treatment-seeking individuals with opioid use disorder ( = 1098). Participants provided oral fluid and urine specimens, which were tested for drugs by liquid chromatography/tandem mass spectrometry. Participants also provided self-reports of fentanyl use. 49.5% tested positive for fentanyl in oral fluid, urine, or both. Of those testing positive for fentanyl, 29.8% were unaware that they had been exposed to fentanyl. Participants testing positive for opioids methadone, and specifically 6-monoacetylmorphine (6-MAM), a unique metabolite of heroin, were significantly more likely to be unaware of fentanyl exposure than participants testing negative for these substances, with a similar trend for oxycodone and tramadol. These findings may be due to fentanyl's effect being difficult to distinguish from that of other opioids, whereas when other types of drugs are adulterated with fentanyl, the differences in effects are likely to be readily discernable. These results support the importance of expanded drug-checking services.

References
1.
Sherman S, Morales K, Park J, McKenzie M, Marshall B, Green T . Acceptability of implementing community-based drug checking services for people who use drugs in three United States cities: Baltimore, Boston and Providence. Int J Drug Policy. 2019; 68:46-53. DOI: 10.1016/j.drugpo.2019.03.003. View

2.
Shulman M, Wai J, Nunes E . Buprenorphine Treatment for Opioid Use Disorder: An Overview. CNS Drugs. 2019; 33(6):567-580. PMC: 6585403. DOI: 10.1007/s40263-019-00637-z. View

3.
Cance J, Adams E, DAmico E, Palimaru A, Fernandes C, Fiellin L . Leveraging the Full Continuum of Care to Prevent Opioid Use Disorder. Prev Sci. 2023; 24(Suppl 1):30-39. PMC: 10689575. DOI: 10.1007/s11121-023-01545-x. View

4.
Safi F, Rioux W, Rider N, Fornssler B, Jones S, Ghosh S . Feasibility and acceptability of inserts promoting virtual overdose monitoring services (VOMS) in naloxone kits: a qualitative study. Harm Reduct J. 2023; 20(1):64. PMC: 10165834. DOI: 10.1186/s12954-023-00792-z. View

5.
Rosano T, Wood M, Hooten W, Rumberger J, Fudin J, Argoff C . Application and Clinical Value of Definitive Drug Monitoring in Pain Management and Addiction Medicine. Pain Med. 2021; 23(4):821-833. DOI: 10.1093/pm/pnab303. View